Addressing Dementia Via Agitation-Centered Evaluation

Phase 2/3 Completed 366 enrolled Axsome Therapeutics, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

Timeline

Start: 2017-07-13
Primary completion: 2020-04-17
Completion: 2020-04-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AXS-05	Unknown	—	Oral
Comparator	Bupropion	Small molecule	—	Oral

Addressing Dementia Via Agitation-Centered Evaluation

Summary

Timeline

Drugs

Indications